The clinical performance of CMT1A is complex and often involves multi-system fatigue. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in linking a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment programs for the treatment and management of the genetic movement sensory neurological disease CMT1A require individualized development, typically including drug therapy, rehabilitation interventions, regular follow-up, and other multidimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many formerly difficult-to-treat neurological disorders have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions and timely adjusted according to disease changes. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of the genetic motor sensory neurological disease (CMT1A). The platform serves a team of internationally authoritative experts in the field of neural systems in China, providing the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.